MIR4327: A Potential Drug Target and Biomarker (G100422891)
MIR4327: A Potential Drug Target and Biomarker
Molecular Intelligence (MOI) has identified a potential drug target and biomarker for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The target, MIR4327, is a protein that is expressed in various tissues and has been associated with various diseases. In this article, we will explore the potential drug target and biomarker for MIR4327, as well as its potential therapeutic applications.
The Protein MIR4327
MIR4327 is a protein that is expressed in various tissues, including the brain, heart, liver, and muscle. It is a member of the miRNA-protein complex (miPOC) and is involved in various cellular processes, including cell signaling, metabolism, and inflammation. MIR4327 has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.
In Cancer
MIR4327 has been shown to promote the growth and survival of various cancer cells, including breast, ovarian, and prostate cancer cells. Several studies have shown that inhibiting MIR4327 can inhibit the growth and survival of cancer cells, including cancer cells that are resistant to traditional cancer treatments. For example, a study by Kim et al. found that inhibiting MIR4327 reduced the growth and survival of human breast cancer cells, while another study by Zhang et al. found that MIR4327 was involved in the development and progression of ovarian cancer.
In Neurodegenerative Diseases
MIR4327 has been associated with the development and progression of various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Several studies have shown that MIR4327 is involved in the development and progression of these diseases, including the development of neurodegeneration and the loss of brain cells. For example, a study by Li et al. found that MIR4327 was involved in the development and progression of Alzheimer's disease, while another study by Wang et al. found that MIR4327 was involved in the development and progression of Parkinson's disease.
In Autoimmune Disorders
MIR4327 has also been associated with the development and progression of various autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. Several studies have shown that MIR4327 is involved in the development and progression of these diseases, including the development of autoimmune inflammation and the loss of immune cells. For example, a study by Nimmerjahn et al. found that MIR4327 was involved in the development and progression of rheumatoid arthritis, while another study by Liu et al. found that MIR4327 was involved in the development and progression of lupus.
The Potential therapeutic Applications
MIR4327 has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a potential drug target, MIR4327 may be used to treat these diseases by inhibiting its activity or increasing its levels in the body. For example, a drug that inhibits MIR4327's activity may be used to treat cancer by suppressing its growth and survival. Similarly, a drug that increases MIR4327's levels may be used to treat neurodegenerative diseases by promoting the growth and survival of brain cells.
As a biomarker, MIR4327 may be used to diagnose and monitor the progression of these diseases. For example, a blood sample from a patient with cancer or neurodegenerative disease may be used to
Protein Name: MicroRNA 4327
The "MIR4327 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR4327 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR4328 | MIR4329 | MIR433 | MIR4330 | MIR4418 | MIR4420 | MIR4423 | MIR4425 | MIR4427 | MIR4428 | MIR4429 | MIR4430 | MIR4431 | MIR4432 | MIR4432HG | MIR4433A | MIR4433B | MIR4435-1 | MIR4435-2 | MIR4435-2HG | MIR4436A | MIR4436B1 | MIR4436B2 | MIR4437 | MIR4440 | MIR4441 | MIR4442 | MIR4443 | MIR4444-1 | MIR4444-2 | MIR4445 | MIR4446 | MIR4447 | MIR4448 | MIR4449 | MIR4450 | MIR4451 | MIR4453 | MIR4453HG | MIR4454 | MIR4455 | MIR4456 | MIR4457 | MIR4458 | MIR4458HG | MIR4463 | MIR4465 | MIR4466 | MIR4467 | MIR4468 | MIR4469 | MIR4470 | MIR4472-1 | MIR4472-2 | MIR4474 | MIR4475 | MIR4476 | MIR4478 | MIR4479 | MIR448 | MIR4481 | MIR4482 | MIR4483 | MIR4484 | MIR4485 | MIR4486 | MIR4487 | MIR4488 | MIR4489 | MIR4491 | MIR4492 | MIR4493 | MIR4496 | MIR4497 | MIR4498 | MIR4499 | MIR449A | MIR449B | MIR449C | MIR4500 | MIR4500HG | MIR4501 | MIR4504 | MIR4505 | MIR4506 | MIR4507 | MIR4508 | MIR4509-1 | MIR4509-2 | MIR4509-3 | MIR450A1 | MIR450A2 | MIR450B | MIR4510 | MIR4511 | MIR4512 | MIR4513 | MIR4514 | MIR4516 | MIR4519
